Penumbra, Inc. (NYSE:PEN) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC increased its position in Penumbra, Inc. (NYSE:PEN) by 211.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 30,582 shares of the company’s stock after acquiring an additional 20,756 shares during the period. Los Angeles Capital Management LLC’s holdings in Penumbra were worth $7,263,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. FMR LLC lifted its holdings in Penumbra by 2.1% in the 3rd quarter. FMR LLC now owns 5,896,396 shares of the company’s stock valued at $1,145,729,000 after acquiring an additional 121,465 shares during the last quarter. Champlain Investment Partners LLC raised its holdings in shares of Penumbra by 20.6% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company’s stock worth $300,786,000 after purchasing an additional 264,122 shares in the last quarter. State Street Corp lifted its stake in Penumbra by 0.3% during the third quarter. State Street Corp now owns 1,236,671 shares of the company’s stock valued at $240,298,000 after purchasing an additional 3,863 shares during the last quarter. RTW Investments LP boosted its holdings in Penumbra by 7.2% during the third quarter. RTW Investments LP now owns 795,750 shares of the company’s stock worth $154,622,000 after buying an additional 53,645 shares in the last quarter. Finally, Baillie Gifford & Co. grew its position in Penumbra by 23.4% in the fourth quarter. Baillie Gifford & Co. now owns 730,233 shares of the company’s stock worth $173,416,000 after buying an additional 138,387 shares during the last quarter. Institutional investors own 88.88% of the company’s stock.

Insider Activity

In other news, Director Harpreet Grewal sold 167 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total transaction of $40,293.76. Following the transaction, the director now owns 8,530 shares in the company, valued at $2,058,118.40. This represents a 1.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Adam Elsesser sold 15,000 shares of Penumbra stock in a transaction on Friday, December 20th. The shares were sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the completion of the sale, the chief executive officer now directly owns 837,582 shares of the company’s stock, valued at approximately $203,498,922.72. The trade was a 1.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,219 shares of company stock worth $4,426,439 in the last three months. 5.00% of the stock is owned by insiders.

Penumbra Stock Up 3.6 %

Penumbra stock opened at $291.80 on Thursday. The firm’s 50 day moving average price is $261.63 and its two-hundred day moving average price is $230.73. The firm has a market cap of $11.24 billion, a PE ratio of 858.24, a P/E/G ratio of 2.83 and a beta of 0.53. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The business had revenue of $315.52 million during the quarter, compared to analyst estimates of $311.63 million. On average, research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PEN. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a research report on Wednesday, February 19th. StockNews.com raised Penumbra from a “hold” rating to a “buy” rating in a research report on Thursday, February 20th. BTIG Research increased their price target on Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Royal Bank of Canada boosted their price objective on Penumbra from $285.00 to $313.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. Finally, Robert W. Baird raised their target price on shares of Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $292.64.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.